Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Leflunomide added to glucocorticoids reduces relapse in IgG4-related disease

Publish date:: June 26, 2019

Key clinical point: Relative to glucocorticoids (GC) alone in IgG4-related disease, adding leflunomide improves efficacy and is well tolerated.

Major finding: At the end of 12 months, relapse rates were lower on leflunomide plus GC versus GC alone (21.2% vs. 50%; P = .023).

Data source: Randomized, open-label, controlled trial.

Disclosures: Dr. Huang and colleagues reported no potential conflicts of interest.

Citation:

Wang Y et al. Ann Rheum Dis. Jun 2019;78(Suppl 2):157. Abstract OPO164, doi: 10.1136/annrheumdis-2019-eular.5717

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Must Reads in Lupus & Connective Tissue Diseases

High-need, high-cost lupus patients described for first time,

Slow taper off antimalarial is best to avoid lupus flare during remission,

Sjögren’s symptom clusters may identify treatment options,

Transcutaneous VNS on the ear shows positive effects in lupus pilot trial,

ASSET extension supports abatacept as treatment for diffuse cutaneous systemic sclerosis,